Provided By GlobeNewswire
Last update: Jul 22, 2025
Tel Aviv, July 22, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (“SciSparc” or the “Company”) (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, reported the receipt on July 18, 2025 of a written notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has regained compliance with Listing Rule 5550(a)(2), which requires the Company’s ordinary shares to maintain a minimum bid price of $1.00 per share.
Read more at globenewswire.comNASDAQ:SPRC (9/11/2025, 2:36:48 PM)
1.9
+0.09 (+4.97%)
Find more stocks in the Stock Screener